CDT Equity details highly dilutive 20% stake in AI firm Sarborg, valued at $115M
CDT is trading near its 52-week low of $2.53 (15% above the low).
Summary
CDT Equity Inc. filed an amendment detailing its acquisition of a 20% stake in Sarborg Limited, an AI company, for $115 million in stock and warrants, plus a deferred $8 million cash payment contingent on future ATM raises.
Updates
· SEC 8-K/A — Sarborg's audited financials show a going concern warning, with $10K cash and $0.8M accumulated deficit as of Dec 31, 2025. Pro forma financials are included.
Key Events · M&A and Partnerships · CDT
-
Acquisition Details Finalized
CDT Equity acquired a 20% stake in Sarborg Limited, an AI company, through an agreement dated February 19, 2026. This follows the company's ongoing efforts to address its financial challenges and Nasdaq listing status.
-
Highly Dilutive Consideration
The investment is valued at $115 million, paid through the issuance of 239.2 shares and pre-funded warrants for 43,991.5 shares (post-reverse split equivalent). The common stock issued had an exercise price of $0.25 per share (post-reverse split equivalent).
-
Deferred Cash Payment
An additional $8 million cash payment is deferred until CDT raises at least $20 million via its existing At-The-Market (ATM) facility, highlighting the company's severe cash constraints and reliance on future capital raises.
-
Significant Pro Forma Dilution
Pro forma financials show a substantial increase in weighted-average common shares outstanding from 3,330 to 47,551.3 (post-reverse split equivalent), reflecting the highly dilutive nature of the transaction.
Analysis · CDT · Life Sciences
This amendment provides the financial details and pro forma impact of CDT Equity's strategic investment in Sarborg Limited, an AI company. While the pivot to AI could be seen as strategic, the terms of the acquisition are highly dilutive for existing shareholders. The $115 million valuation for a 20% stake, paid in stock and warrants, represents a substantial capital outlay for a company already facing severe financial distress, a Nasdaq delisting threat, and a going concern warning. The deferred $8 million cash payment, contingent on future ATM raises, further highlights CDT's precarious cash position and reliance on ongoing dilution. Sarborg itself has going concern issues and relies entirely on CDT for revenue, raising questions about the quality of the acquired asset. The pro forma financials show a massive increase in share count, indicating significant dilution.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $2.90 on NASDAQ in the Life Sciences sector. The 52-week trading range was $2.53 to $3,460.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.